ISIN: GB0033856740 WKN: A0BKRH Sinclair Pharma plc is an international specialty pharmaceutical company.
23.12.2011 - 15:20:50SINCLAIR. It has a growing sales and marketing operation that is already present in France, Italy, the UK, Spain and Portugal, and a complementary marketing partner network that spans 82 countries.
Sinclair has expertise in acquiring or developing commercially attractive and undervalued products, registering these products and bringing them to market in a short time frame.The company focuses on niche therapeutic areas and its current portfolio includes products in dermatology and oral health.
Sinclair’s products can be divided into five groups: Oral Health, Dermatology, Oncology, Pipeline and Others. The company is experiencing strong sales growth, particularly for its flagship products Atopiclair (eczema/atopic dermatitis), Decapinol (gingivitis/gum disease) and Aloclair (mouth ulcers).
The Sinclair portfolio includes20 registered products in the EU and 11 in the US. There have been over 20 product launches globally since July 2005, and the pipeline includes more than 14 products currently in development.
Headquartered in Godalming, Surrey, Sinclair Pharmaceuticals Limited was founded in 1971 by Andrew Sinclair to focus on the sale and marketing of generic and branded pharmaceutical products in the UK.
The company operated in this way until August 2000 when Sinclair Pharmaceuticals Limited was acquired by a management team led by Dr. Michael Flynn and Jerry Randall. Sinclair Pharma was re-registered as a public limited company on 28 November 2003.
Sinclair’s products can be divided into five groups: Oral Health, Dermatology, Oncology, Pipeline and Others. The company is experiencing strong sales growth, particularly for its flagship products Atopiclair (eczema/atopic dermatitis), Decapinol (gingivitis/gum disease) and Aloclair (mouth ulcers).
The Sinclair portfolio includes20 registered products in the EU and 11 in the US. There have been over 20 product launches globally since July 2005, and the pipeline includes more than 14 products currently in development.
Headquartered in Godalming, Surrey, Sinclair Pharmaceuticals Limited was founded in 1971 by Andrew Sinclair to focus on the sale and marketing of generic and branded pharmaceutical products in the UK.
The company operated in this way until August 2000 when Sinclair Pharmaceuticals Limited was acquired by a management team led by Dr. Michael Flynn and Jerry Randall. Sinclair Pharma was re-registered as a public limited company on 28 November 2003.
